Gauss

MILLIPLEX Human Immuno-Oncology Checkpoint Protein Premixed 17-plex - Immuno-Onco Multiplex Assay - Luminex technology

Réf. UGAP : 4068414 Réf. Fournisseur : HCKP1-11K-PX17 Réf. Constructeur : HCKP1-11K-PX17
MILLIPLEX Human Immuno-Oncology Checkpoint Protein Premixed 17-plex - Immuno-Onco Multiplex Assay - Luminex technology
MILLIPLEX Human Immuno-Oncology Checkpoint Protein Premixed 17-plex - Immuno-Onco Multiplex Assay - Luminex technology
Franco de port et d'emballage pour toutes les commandes supérieures à 80€ HT.


Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
La quantité choisie doit être comprise entre 1 et 999 999.
Il ne reste que 0 exemplaires.

Points clés

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.The MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 is a 17-plex kit to be used for the simultaneous quantification of all of the following analytes in serum, plasma and tissue culture samples: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2). Produit à destination de la recherche uniquement

En savoir plus

Garantie

Garantie 0 Mois

Description

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.The MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 is a 17-plex kit to be used for the simultaneous quantification of all of the following analytes in serum, plasma and tissue culture samples: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2). Produit à destination de la recherche uniquement

Caractéristiques

Fournisseur
SIGMA ALDRICH CHIMIE
Marque
MILLIPORE
Nomenclature CNRS
NA32
Nomenclature INSERM
NA.NA32
Nomenclature DGOS
LD10AOOO
Lieu de stockage
France
Température de conservation (°C)
2-8 °C
Code à barre
oui
Nomenclature Nacres
NA.32
Quantité
N/A
Délai de péremption à la date de livraison
12 mois
Nomenclature CEA
SGP01
Soumis à carboglace
non
Référence fabricant
HCKP1-11K-PX17
Lieu de fabrication
États-Unis
Nomenclature CHU
18.551
Référence distributeur
HCKP1-11K-PX17
Reprise en cas d’erreur client
non
Nomenclature IRSN
273
Vendu par
1 kit